Back to results
US 12,594,273 B2Granted
Intranasal DHE for the treatment of headache
AssigneeSatsuma Pharmaceuticals, Inc.
InventorsShunji Haruta, Nikhilesh N. Singh, John Kollins, Salvador Rico
Life of this patent
Estimating the term…
Abstract
Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.
Claims16
A nasal delivery device, comprising
- a pharmaceutical nasal dosage form comprising dihydroergotamine mesylate and microcrystalline cellulose;
- wherein dihydroergotamine mesylate is present in the pharmaceutical nasal dosage form in an amount of 6 mg to about 8 mg,
- wherein said microcrystalline cellulose is present in the pharmaceutical nasal dosage form in an amount from about 40% to about 60% w/w;
- and
- wherein said pharmaceutical nasal delivery device provides a Tmax of dihydroergotamine mesylate of less than or equal to about 30 minutes;
- and
- the nasal delivery device requires no priming.
4 more elements
Dependencies are inferred from the claim text.